Quadira Biosciences is at the forefront of therapeutic Antibody Drug Conjugate (ADC) development, leveraging two advanced technology platforms to expedite the creation and preclinical evaluation of new ADCs. This innovative approach allows the company to complete the development of ten new ADCs within just four months each, significantly enhancing the commercial lifecycle of antibody drugs. The technologies employed include a novel type of click chemistry and a unique physiological 3D modeling approach, which together facilitate the design, screening, and definition of highly effective therapeutic ADCs. The company’s portfolio is projected to have a market value of $25 billion, underscoring the potential impact of their advancements in this field.

One of Quadira Biosciences' flagship products is QBK249-G, an anti-HER-2 ADC that demonstrates remarkable antitumor activity against HER2-positive solid breast tumors. Preclinical studies indicate that QBK249-G exhibits an eight-fold increase in antitumor efficacy compared to existing ADCs, while maintaining comparable toxicity at a significantly lower concentration. This product not only shows promise in treating active tumors but also effectively targets dormant tumor cells, highlighting the platform's efficiency and speed in drug development. As QBK249-G moves through the patenting process and prepares for licensing, Quadira Biosciences continues to advance its pipeline with additional ADCs entering preclinical evaluation.

Switzerland

Quadira Biosciences combines two outstanding cutting-edge technology platforms to complete the development and preclinical studies of ten new Antibody Drug Conjugates (ADCs) within 4 months each. This dramatically extend the previously rather limited commercial lifecycle of  antibody drugs. Collectively, the planned ADC portfolio has a market value of $25 billion. The first new anti-HER-2 ADC has already been completed and documented in the last four months and is currently being prepared for licensing. 

Quadira Biosciences

Company Details